Si-Bone Inc (SIBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Si-Bone Inc (SIBN) has a cash flow conversion efficiency ratio of -0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.36 Million) by net assets ($178.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Si-Bone Inc balance sheet independence to measure how much of total assets are equity-financed.
Si-Bone Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Si-Bone Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SIBN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Si-Bone Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Si-Bone Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capital Bancorp
NASDAQ:CBNK
|
0.053x |
|
Sunrise Energy Metals Ltd
AU:SRL
|
-0.278x |
|
SandRidge Energy Inc
NYSE:SD
|
0.038x |
|
Shengtak New Material Co Ltd
SHE:300881
|
-0.093x |
|
Anhui Landun Photoelectron Co Ltd
SHE:300862
|
0.007x |
|
KraussMaffei Co Ltd
SHG:600579
|
0.016x |
|
Shandong Shuangyi Technology Co Ltd
SHE:300690
|
0.025x |
|
Amtran Technology Co Ltd
TW:2489
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Si-Bone Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Si-Bone Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see SIBN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $177.53 Million | $-675.00K | -0.004x | +94.89% |
| 2024-12-31 | $166.96 Million | $-12.43 Million | -0.074x | +32.64% |
| 2023-12-31 | $169.38 Million | $-18.71 Million | -0.110x | +73.93% |
| 2022-12-31 | $98.30 Million | $-41.66 Million | -0.424x | -44.08% |
| 2021-12-31 | $134.42 Million | $-39.53 Million | -0.294x | -62.45% |
| 2020-12-31 | $169.36 Million | $-30.66 Million | -0.181x | +63.93% |
| 2019-12-31 | $63.01 Million | $-31.63 Million | -0.502x | -211.81% |
| 2018-12-31 | $90.19 Million | $-14.52 Million | -0.161x | -218.81% |
| 2017-12-31 | $-129.38 Million | $-17.53 Million | 0.135x | -12.06% |
| 2016-12-31 | $-108.73 Million | $-16.75 Million | 0.154x | +101.86% |
| 2015-12-31 | $3.23 Million | $-26.72 Million | -8.264x | -116.34% |
| 2014-12-31 | $6.89 Million | $-26.33 Million | -3.820x | -1215.61% |
| 2013-12-31 | $-1.65 Million | $-566.00K | 0.342x | -- |
About Si-Bone Inc
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium … Read more